Structure Therapeutics, Inc. (GPCR)

35.52 -0.41 (-1.14%) USD  |  NASDAQ  |  Sep 28, 14:16
More

Structure Therapeutics Cash from Operations (Annual) : -222.79M for Dec. 31, 2025

Cash from Operations (Annual) Chart

View Cash from Operations (Annual) for GPCR.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Annual) Chart
Start Trial

Historical Cash from Operations (Annual) Data

View and export this data back to 2020. Start Trial.
Date Value
December 31, 2025 -222.79M
December 31, 2024 -116.69M
December 31, 2023 -79.42M
Date Value
December 31, 2022 -46.07M
December 31, 2021 -32.20M
December 31, 2020 -14.31M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Annual) Range, Past 5 Years

View Cash from Operations (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Annual) Benchmarks

View Cash from Operations (Annual) Benchmarks
Start Trial
Eli Lilly & Co. 16.81B
Novo Nordisk A/S 18.01B
Pfizer Inc. 11.70B
Viking Therapeutics, Inc. -278.68M
Johnson & Johnson 24.53B